Cathie Wood’s ARK sells Figma stock, buys Scribe Therapeutics By Investing.com
According to ARK’s published trades for July 24, 2026, ARK sold 718,303 shares of Figma Inc (FIG) for about $14.37M across ARKK and ARKW. It bought 361,253 shares of Scribe Therapeutics (SCTX) for about $5.42M and added to Compass Pathways (CMPS) for about $1.25M. It also sold ATAI Beckley (ATAI) and bought Kodiak AI (KDK), Pony AI (PONY), X-Energy (XE), and others.
How this was made
The 30-second read
Why it matters
For traders, the actionable element is ETF flow and sentiment read-through from disclosed buys/sells. However, there are no accompanying company fundamentals (earnings, trials, approvals, contracts) in the text, limiting decision usefulness.
Market read
This is primarily a disclosed ETF positioning update, useful for short-term sentiment/flow monitoring rather than fundamental repricing.
What to watch
The article provides trade sizes but not whether these are net-new positions, cost-basis changes, or whether other funds are doing the opposite; without that, price impact may be overstated.
Background
The piece summarizes ARK ETF daily trades for July 24, 2026, including sizable sales of Figma and ATAI and purchases of Scribe Therapeutics and other names.
Ticker impact
ARK sold 718,303 Figma shares across ARKK and ARKW for about $14.37M, signaling a material reduction in its position.
Mild negative to neutral near-term, with impact likely limited unless follow-on selling continues.
This is a disclosed ETF trade (not fundamentals), and the article provides size and dollar value but no price reaction or new company-specific catalyst.
ARK bought 361,253 Scribe Therapeutics shares via ARKG for about $5.42M, highlighting a new biotech allocation.
Mild positive near-term if traders treat ARK activity as a signal; otherwise limited fundamental impact.
The trade size is specific, but there is no accompanying clinical, regulatory, or financial datapoint in the text.
ARK sold 758,353 ATAI Beckley shares through ARKG for about $5.44M, continuing a stated reduction trend.
Mild negative to neutral near-term, mainly sentiment/flow related.
The article provides transaction details but no new ATAI-specific news beyond the fund’s positioning change.
ARK purchased 107,121 Compass Pathways shares via ARKG for about $1.25M, indicating continued confidence per the article.
Slight positive bias near-term, likely modest without additional catalysts.
The position size is smaller and the article lacks any new CMPS operational or clinical information.
ARK bought 47,500 Kodiak AI shares via ARKQ for about $0.20M, adding small exposure to AI-driven tech.
Negligible to mild positive near-term.
Dollar value is very small and the article provides no company-specific catalyst.
ARK bought 40,404 Pony AI shares via ARKQ for about $0.30M, adding incremental exposure.
Negligible near-term impact.
The article provides trade size but no new PONY-specific news.
ARK increased X-Energy by buying 120,704 shares across ARKK and ARKQ for about $1.92M, reflecting added nuclear interest.
Mild positive near-term, likely limited unless more buying follows.
The trade is specific, but the article contains no new XE milestones, contracts, or regulatory developments.
ARK bought 5,264 Bitmine Immersion Technologies shares via ARKK for about $87k, a very small position change.
Negligible near-term impact.
The article discloses a trade but provides no additional BMNR catalyst and the size is minimal.
Market effects
Signals ARK rotation toward biotech (SCTX) and AI/adjacent themes, while trimming design software (FIG) and certain biotech exposure (ATAI).
No explicit regional macro or cross-market catalyst beyond US-listed names mentioned.
Limited global relevance; this is primarily ETF positioning rather than a company-level global event.
Counterpoint
ARK trades can be driven by portfolio rebalancing, risk limits, or ETF flow mechanics, so the trades may not reflect a new fundamental view on FIG, ATAI, or SCTX.
Key entities
- ETFARK ETFs (ARKK, ARKW, ARKG, ARKQ)
The funds executing the disclosed trades that drive the positioning signals in the article.
- EquityFigma Inc
Subject of a large ARK sale disclosed in the article.
- EquityScribe Therapeutics Inc
Subject of a disclosed ARK purchase in the article.
- EquityATAI Beckley Inc
Subject of a disclosed ARK sale in the article.
- EquityCompass Pathways PLC
Subject of a disclosed ARK purchase in the article.
